What does the company Align do?
Align Technology is a global medical device company that is changing lives through better smiles. We reimagine and reinvent the way orthodontic and restorative treatment is presented and delivered to millions of people around the world.
Who owns Align Technology?
Align Technology
| Type | Public |
|---|---|
| Founders | Zia Chishti Kelsey Wirth |
| Headquarters | Tempe, Arizona, U.S. |
| Area served | Worldwide |
| Key people | Joe Hogan (President & CEO) |
Why is Align Technology stock dropping?
The company had net income of $168.7 million, which was down 29.7% sequentially and 33% year over year. CEO Joe Hogan said there were several factors for the drop: COVID lockdowns, particularly in China; weaker consumer confidence in the United States; inflationary pressures; and the Russia/Ukraine conflict.
Is Align Technology Incorporated?
Align Technology, Inc. Company was founded and work began on the development of a clear aligner.
Is Align a prescription drug?
Insurance coverage usually is not offered for over-the-counter (OTC) drugs like Align. There may be cases where your doctor writes a prescription for Align, but otherwise, pharmacy coupons are probably the most affordable option when buying Align.
Who are Align Technology Competitors?
Align Technology competitors include SmileDirectClub, Henry Schein, 3M and DENTSPLY SIRONA.
How many patents does Align Technology have?
2755 patents
Align Technology has a total of 2755 patents globally. These patents belong to 559 unique patent families. Out of 2755 patents, 1942 patents are active.
Is Align a buy?
As it turns out, over the last five years Align’s annual net income has grown by 234%, and there’s no indication that the favorable trend is petering out; nor is there cause to think that it will anytime soon. In my view, Align is a great stock to buy this year for investors who want growth.
Is Align Technology a good buy?
Currently, Align Technology, Inc.’s price-earnings ratio is 29.1. Align Technology, Inc.’s trailing 12-month revenue is $4.0 billion with a 17.5% profit margin. Year-over-year quarterly sales growth most recently was 8.8%. Analysts expect adjusted earnings to reach $9.989 per share for the current fiscal year.
Who owns Invisalign patent?
Align Technologies
The Invisalign Patents Invisalign is owned by its parent company Align Technologies. Over the years they have been stockpiling patents aimed at protecting their intellectual properties from likely competitors. Currently, Invisalign has over 400 patents!
Who is the parent company of Invisalign?
Invisalign is manufactured by Align Technology, an American multinational medical-device company. The company’s clear align system has been used to treat more than 3 million patients.
Who should not take Align?
Align Contraindications This medicine is not right for everyone. Do not use it if you had an allergic reaction to a probiotic, such as acidophilus, bifidobacterium, lactobacillus, saccharomyces, or streptococcus thermophilus.
Can you buy Align over the counter?
Align is a brand-name over-the-counter probiotic supplement used to upkeep a normal balance of bacteria in your digestive system. No generic version of Align is currently available. The average cash price of Align is $33.10 for 1, 24 Tablets Chewable Tablet Chewable.
How much do 3M clarity aligners cost?
How much do clear braces cost?
| Brand | Fixed brace or removable aligner? | Cost estimate |
|---|---|---|
| Invisalign | In-office removable aligner | $3,500 – $8,500 |
| Damon Clear | Fixed | $3,800 – $8,000 |
| 3M Clarity | Fixed | $2,200 – $4,700 |
| Radiance Plus | Fixed | $2,500 – $5,000 |
Why did Invisalign lose their patent?
Did it take twenty years for other companies to figure out Invisalign’s technology? No. The reality is that in October of 2017, more than 40 patents held by Invisalign expired. Suddenly, the market was open for competition, and competitors flooded the space.
Is Align Technology A Good Investment?
In my view, Align is a great stock to buy this year for investors who want growth. But be aware that it has been hit particularly hard by the ongoing drama surrounding the Federal Reserve’s plans to hike interest rates, as have most growth stocks. So it might not beat the market, at least for the time being.
What is Invisalign trading at?
Align Technology (ALGN) closed at $230.31 in the latest trading session, marking a -1.77% move from the prior day.
How much is Invisalign company worth?
$20 billion
The shift to clear aligners has powered Align Technology (ALGN), the company behind Invisalign, to a record year. Align’s value has nearly tripled, making it the top performer on the S&P 500. It’s worth close to $20 billion.
Did Invisalign lose their patent?
And last October, Invisalign lost its exclusivity on 40 patents that kept it as the leading clear-aligner brand, opening the door for newcomers such as SmileDirectClub.
Is Invisalign FDA approved?
Has the FDA approved Invisalign treatment? Yes, Invisalign aligners are classified as Class II medical devices by the U.S. Food and Drug Administration (FDA). Align Technology, Inc. received the necessary 510(k) clearance from the FDA to sell and market Invisalign treatment in 1998.